Synthesis and Antiinflammatory Activity of 7-Methanesulfonylamino-6-phenoxychromones. Antiarthritic Effect of the 3-Formylamino Compound (T-614) in Chronic Inflammatory Disease Models.
作者:Takihiro INABA、Keiichi TANAKA、Ryuko TAKENO、Hideyoshi NAGAKI、Chosaku YOSHIDA、Shuntaro TAKANO
DOI:10.1248/cpb.48.131
日期:——
A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized with 4-chloro-3-nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2', 4'-difluoro derivatives (9a and 9d), and 3-formylamino derivative (19a) and its 2'-fluoro and 2', 4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1mg/kg/d for 7d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective diseasemodifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.
通过4-氯-3-硝基茴香醚合成了7-甲磺酰氨基-6-苯氧基色酮(1)的吡喃酮和苯氧基环的一系列衍生物,并在动物口服给药中评价了它们对急性和慢性炎症的作用。2'-氟和2',4'-二氟衍生物(9a和9d)、3-甲酰氨基衍生物(19a)及其2'-氟和2',4'-二氟化合物(22a和22d)在角叉菜胶诱发的水肿(CPE)和佐剂诱发的关节炎(AA)大鼠模型中显示出显著的效力。AA治疗效果ED40=2.5-7.1mg/kg/d,持续7天,AA预防效果在3mg/kg/d剂量下抑制53-70%,持续22天。为了确定进一步药理学研究的候选药物,对这五种化合物进行了胃溃疡形成倾向的评估,从而选择了在口服给药300mg/kg时未引起急性溃疡的大鼠无氟化合物19a。化合物19a(在已建立的AA中的ED40=3.6mg/kg)对DBA/1J小鼠的II型胶原诱导的关节炎具有良好的治疗效果,剂量为30和100mg/kg,表明19a(指定为T-614)作为有前途的疾病修饰性抗风湿药物的开发。此外,已建立了T-614的制备规模合成路线。